Email this article 
Lipid, Adipokine аnd Ghrelin Concentrations in Myocardial Infarction Patients with Insulin Resistance
- Authors: Gruzdeva O.V.1, Karetnikova V.N.2, Akbasheva O.Е.3, Fedorova T.S.3, Belik E.V.1, Palicheva E.I.2, Uchasova E.G.1, Dyleva Y.A.1, Brazovskaya N.G.3, Barbarash O.L.2
-
Affiliations:
- Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
- Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation Kemerovo State Medical Academy, Russian Federation
- Siberian State Medical University, Tomsk, Russian Federation
- Issue: Vol 68, No 7 (2013)
- Pages: 13-19
- Section: CARDIOLOGY AND CARDIOVASCULAR SURGERY: CURRENT ISSUES
- URL: https://vestnikramn.spr-journal.ru/jour/article/view/162
- DOI: https://doi.org/10.15690/vramn.v68i7.706
- ID: 162
Cite item
Full Text
Abstract
Aim. The estimate insulin resistance in myocardial infarction. Patients and methods. The study involved 200 patients with myocardial infarction, in which on the 1st and 12th day of hospitalization measured glucose, insulin, insulin resistance index (IR), lipid profile, the concentration of adipokines and ghrelin. Results. IR was detected in 77% of patients and was associated with a history of factors of cardiovascular risk, adverse clinical course of the disease, lipid disorders. The most important marker was the level of free fatty acids. High risk associated with increased in 9 times the concentration of free fatty acids in blood plasma. Patients with IR observed increased concentrations of leptin, resistin, and reduced the protective effect of adiponectin. The high specificity and sensitivity characteristic of the concentration of ghrelin: its reduction by 4 times in the acute phase of myocardial infarction increases the risk of MI by 78%. Conclusions. Significant risk factors for MI myocardial infarction, along with insulinemia and glycemia, is to increase the concentration of free fatty acids and the disbalance in the system adipokines against deficiency of ghrelin in acute and early recovery periods of the disease. Free fatty acids and ghrelin are promising markers to stratify the risk of insulin resistance in patients with myocardial infarction.
About the authors
O. V. Gruzdeva
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
Author for correspondence.
Email: gruzov@cardio.kem.ru
PhD, Department of Diagnostics of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS
Address: 650002, Kemerovo, Sosnovy Blvd., 6; tel.: (3842) 64-05-53
V. N. Karetnikova
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian FederationKemerovo State Medical Academy, Russian Federation
Email: tori1071@mail.ru
PhD, Head of the Laboratory of Blood Circulation Pathology of Multifocal Atherosclerosis, Department of Multifocal Atherosclerosis Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS, Professor, Department of Cardiology and Cardiovascular Surgery, Kemerovo State Medical
Address: 650002, Kemerovo, Sosnovy Blvd., 6; tel.: (3842) 64-05-53 Russian Federation
O. Е. Akbasheva
Siberian State Medical University, Tomsk, Russian Federation
Email: akbashoe@yandex.ru
PhD, Associate Professor, Department of Biochemistry, Siberian State Medical University Address: 634050, Tomsk, Moscow path, 6; tel.: (3822) 42-09-22
Russian FederationT. S. Fedorova
Siberian State Medical University, Tomsk, Russian Federation
Email: akbashoe@yandex.ru
PhD, Associate Professor, Department of Biochemistry, Siberian State Medical University. Address: 634050, Tomsk, Moscow path, 6; tel.: (3822) 42-09-22
Russian FederationE. V. Belik
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
Email: sionina.ev@mail.ru
Junior Research Worker, Department of Diagnostics of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS
Address: 650002, Kemerovo, Sosnovy Blvd., 6; tel.: (3842) 64-05-53
E. I. Palicheva
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian FederationKemerovo State Medical Academy, Russian Federation
Email: palichevaelena@rambler.ru
PhD, Senior Research Worker, Department of Diagnostics of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS, Associate Professor, Department of Biochemistry, Kemerovo State Medical Academy
Address: 650002, Kemerovo, Sosnovy Blvd., 6; tel.: (3842) 64-05-53
E. G. Uchasova
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
Email: uchaeg@cardio.kem.ru
PhD, Senior Research Worker, Department of Diagnostics of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS
Address: 650002, Kemerovo, Sosnovy Blvd., 6; tel.: (3842) 64-05-53 Russian Federation
Yu. A. Dyleva
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
Email: dileya@cardio.kem.ru
Junior Research Worker, Department of Diagnostics of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS
Address: 650002, Kemerovo, Sosnovy Blvd., 6; tel.: (3842) 64-05-53
N. G. Brazovskaya
Siberian State Medical University, Tomsk, Russian Federation
Email: brand@mail.ru
PhD, Senior Lecturer, Department of Medical and Biological Cybernetics, Siberian State Medical University
Address: 634050, Tomsk, Moscow path, 6; tel.: (3822) 42-09-22 Russian Federation
O. L. Barbarash
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian FederationKemerovo State Medical Academy, Russian Federation
Email: barbol@cardio.kem.ru
PhD, Professor, Director of the Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS, Head of Multifocal Atherosclerosis Department Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS, Head of the Department of Cardiology and Cardiovascular Surgery, Kemerovo State Medical Academy
Address: 650002, Kemerovo, Sosnovy Blvd., 6; tel.: (3842) 64-33-08
References
- Lazzeri C., Sori A., Chiostri M., Gensini GF, Valente S. Prognostic role of insulin resistance as assessed by homeostatic model assessment index in the acute phase of myocardial infarction in nondiabetic patients submitted to percutaneous coronary intervention. Eur. J. Anaesthesiol. 2009; 26: 856–862.
- Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., Quon M.L. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 2000; 85: 2402–2410.
- Gruzdeva O., Uchasova E., Dyleva Y., Belik E., Kashtalap V., Barbarash O. Relationship between free fatty acids, insulin resistance markers, and oxidized lipoproteins in myocardial infarction and acute left ventricular failure. Diabetes, Metabol. Syndr. & Obesity: Targets & Therapy. 2013; 6: 103–111.
- Rask-Madsen C., Kahn C. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2012; 32: 2052–2059.
- Dunmore S., Brown J. The role of adipokines in β-cell failure of type 2 diabetes. J. Endocrinol. 2013; 216: 37–45.
- Varela L., Va´zquez M., Cordido F., Nogueiras R, Vidal-Puig A., Die´guez C., Lo´pez M. Ghrelin and lipid metabolism: key partners in energy balance. J. Mol. Endocrinol. 2011; 46: 43–63.
- Stubbs P., Nishio K., Shigemitsu M., Kusuyama T., Fukui T., Kawamura K., Itoh S., Konno N., Katagiri T. Insulin resistance in nondiabetic patients with acute myocardial infarction. Cardiovasc. Revasc. Med. 2006; 7 (2): 54–60.
- Leclercq I., Da Silva Morais A., Schroyen B., Van Hul N., Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J. Hepatol. 2007; 47: 142–156.
- Deng Y., Scherer P. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann. N.Y. Acad. Sci. 2010; 1212: 1–19.
- Koh K., Park S., Quon M. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008; 117: 3238–3249.
- Opie L. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation. 2008; 117: 2172–2177.
- Рichi S. Resistin down-regulates insulin-mediated glucose uptake by target tissues. Endocr. Res. 2010; 23: 132–137.
- Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006; 116: 1784–1792.
- Lee H., Wang G., Englander E., Kojima M., Greeley G. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: Enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology. 2002; 143: 185–190.
- Pacifico L., Poggiogalle E., Costantino F., Anania C., Ferraro F., Chiarelli F., Chiesa C. Acylated and nonacylated ghrelin levels and their associations with insulin resistance in obese and normal weight children with metabolic syndrome. Eur. J. Endocrinol. 2009; 161: 861–870.
- Doogue M., Begg E., Moore M., Lunt H., Pemberton C. et al. Metformin increases plasma ghrelin in Type 2 diabetes. Brit. J. Clin. Pharmacol. 2009; 68: 875–882.
- Granata R., Isgaard J., Alloatti G., Ghigo E. Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp. Biol. Med. 2011; 236: 505–514.
- Dixit V., Schaffer E., Pyle R. Ghrelin ingibits leptin and activation induced proinflammatory cytokine expression by human monocytes and T-cells. J. Clin. Invest. 2004; 114: 57–66.
Supplementary files
